Search

Your search keyword '"Holowiecka-Goral, Aleksandra"' showing total 18 results
Start Over Author "Holowiecka-Goral, Aleksandra"
18 results on '"Holowiecka-Goral, Aleksandra"'

1. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation

Author

Giebel, Sebastian, Nowak, Izabela, Dziaczkowska, Joanna, Czerw, Tomasz, Wojnar, Jerzy, Krawczyk-Kulis, Malgorzata, Holowiecki, Jerzy, Holowiecka-Goral, Aleksandra, Markiewicz, Miroslaw, Kopera, Malgorzata, Karolczyk, Agnieszka, Kyrcz-Krzemien, Slawomira, and Kusnierczyk, Piotr more...

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results

3. Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial

Author

Pluta, Agnieszka, primary, Robak, Tadeusz, additional, Wrzesien-Kus, Agata, additional, Katarzyna Budziszewska, Bozena, additional, Sulek, Kazimierz, additional, Wawrzyniak, Ewa, additional, Czemerska, Magdalena, additional, Zwolinska, Malgorzata, additional, Golos, Aleksandra, additional, Holowiecka-Goral, Aleksandra, additional, Kyrcz-Krzemien, Slawomira, additional, Piszcz, Jaroslaw, additional, Kloczko, Janusz, additional, Mordak-Domagala, Monika, additional, Lange, Andrzej, additional, Razny, Małgorzata, additional, Madry, Krzysztof, additional, Wiktor-Jedrzejczak, Wieslaw, additional, Grosicki, Sebastian, additional, Butrym, Aleksandra, additional, Kuliczkowski, Kazimierz, additional, Warzocha, Krzysztof, additional, Holowiecki, Jerzy, additional, Giebel, Sebastian, additional, Szydlo, Richard, additional, and Wierzbowska, Agnieszka, additional more...

Published
2017
Full Text
View/download PDF

4. Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study

Author

Budziszewska, Bozena Katarzyna, primary, Pluta, Agnieszka, additional, Sulek, Kazimierz, additional, Wierzbowska, Agnieszka, additional, Robak, Tadeusz, additional, Giebel, Sebastian, additional, Holowiecka-Goral, Aleksandra, additional, Sawicki, Waldemar, additional, Ejduk, Anna, additional, Patkowska, Elzbieta, additional, Manko, Joanna, additional, Gajkowska-Kulik, Justyna, additional, Piszcz, Jaroslaw, additional, Mordak-Domagala, Monika, additional, Madry, Krzysztof, additional, Holowiecki, Jerzy, additional, Kyrcz-Krzemien, Slawomira, additional, Nowakowska-Domagala, Maria, additional, Dmoszynska, Anna, additional, Calbecka, Malgorzata, additional, Kloczko, Janusz, additional, Wiktor Jędrzejczak, Wiesław, additional, Lange, Andrzej, additional, Razny, Malgorzata, additional, Bilinski, Przemyslaw, additional, Warzocha, Krzysztof, additional, and Lech-Maranda, Ewa, additional more...

Published
2015
Full Text
View/download PDF

5. Daunorubicine, Cytarabine and Cladribine (DAC) Vs Daunorubicine and Cytarabine (DA) Induction Treatment in Elderly Acute Myeloid Leukemia (AML) Patients – Results of the Prospective, Multicenter, Randomized Trial of the Polish Adult Leukemia Group (PALG)

Author

Pluta, Agnieszka, primary, Robak, Tadeusz, additional, Wrzesien-Kus, Agata, additional, Budziszewska, Bozena Katarzyna, additional, Sulek, Kazimierz, additional, Wawrzyniak, Ewa, additional, Czemerska, Magdalena, additional, Zwolinska, Malgorzata, additional, Golos, Aleksandra, additional, Holowiecka-Goral, Aleksandra, additional, Kyrcz-Krzemien, Slawomira, additional, Piszcz, Jaroslaw, additional, Kloczko, Janusz, additional, Mordak, Monika, additional, Lange, Andrzej, additional, Razny, Małgorzata, additional, Madry, Krzysztof, additional, Wiktor-Jedrzejczak, Wieslaw, additional, Grosicki, Sebastian, additional, Butrym, Aleksandra, additional, Kuliczkowski, Kazimierz, additional, Warzocha, Krzysztof, additional, Holowiecki, Jerzy, additional, and Wierzbowska, Agnieszka, additional more...

Published
2012
Full Text
View/download PDF

7. Liposomal cytarabine in advanced-stage acute lymphoblastic leukemia and aggressive lymphoma with central nervous system involvement: experience of The Polish Acute Leukemia Group

Author

Holowiecka-Goral, Aleksandra, primary, HOłowiecki, Jerzy, additional, Giebel, Sebastian, additional, Stella-Holowiecka, Beata, additional, Krawczyk-Kulis, Małgorzata, additional, Kos, Kinga, additional, Lehmann-Kopydłowska, Agata, additional, Dudziński, Marek, additional, Hałasz, Magdalena, additional, Preisner, Witold, additional, Cioch, Maria, additional, and Piszcz, Jarosław, additional more...

Published
2009
Full Text
View/download PDF

8. Survival Benefit of Post Induction Consolidation Therapy in MCL (Mantle Cell Lymphoma): a Polish Lymphoma Research Group (PLRG) Retrospective Multicenter Analysis

Author

Jurczak, Wojciech, primary, Giza, Agnieszka, primary, Krochmalczyk, Dorota, primary, Zimowska-Curylo, Dagmara, primary, Sobocinski, Marcin, primary, Stella-Holowiecka, Beata, primary, Holowiecka-Goral, Aleksandra, primary, Boguradzki, Piotr, primary, Kisiel, Elzbieta, primary, Mazur, Grzegorz, primary, Wrobel, Tomasz, primary, Knopinska-Posluszny, Wanda, primary, Warzocha, Ewa Kalinka -, primary, and Skotnicki, Aleksander B., primary more...

Published
2008
Full Text
View/download PDF

9. The Impact of NOD2/CARD15 and KIR Polymorphisms on the Incidence of Infectious Complications in allo-HSCT Recipients.

Author

Holowiecka-Goral, Aleksandra, primary, Giebel, Sebastian, additional, Nowak, Izabela, additional, Czerw, Tomasz, additional, Wojnar, Jerzy, additional, Krawczyk-Kulis, Malgorzata, additional, Pietruszka, Elzbieta, additional, Markiewicz, Miroslaw, additional, Kusnierczyk, Piotr, additional, Wylezol, Iwona, additional, and Prof, Jerzy Holowiecki, additional more...

Published
2007
Full Text
View/download PDF

10. Increasing Efficacy of Autologous Haematopoetic Cell Transplantation in Acute Myeloblastic Leukaemia; a Single Centre Experience in 141 Patients.

Author

Prof, Jerzy Holowiecki, primary, Czerw, Tomasz, additional, Wojnar, Jerzy, additional, Krawczyk-Kulis, Malgorzata, additional, Grosicki, Sebastian, additional, Stella-Holowiecka, Beata, additional, Prof, Slawomira Kyrcz-Krzemien, additional, Sadus-Wojciechowska, Maria, additional, Giebel, Sebastian, additional, Kachel, Lucja, additional, Wozniczka, Krzysztof, additional, and Holowiecka-Goral, Aleksandra, additional more...

Published
2007
Full Text
View/download PDF

11. Treosulfan, Fludarabine, and Antithymocyte Globulin - A Low Toxicity Conditioning Regimen for Unrelated Donor - Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia.

Author

Holowiecki, Jerzy, primary, Giebel, Sebastian, additional, Wojnar, Jerzy, additional, Markiewicz, Miroslaw, additional, Holowiecka-Goral, Aleksandra, additional, Wylezol, Iwona, additional, Krawczyk-Kulis, Malgorzata, additional, and Wozniczka, Krzysztof, additional more...

Published
2006
Full Text
View/download PDF

12. Impaired Survival after Unrelated Hematopoietic Stem Cell Transplantation from KIR2DS1 and KIR2DS2 Positive Donors.

Author

Giebel, Sebastian, primary, Czerw, Tomasz, additional, Nowak, Izabela, additional, Wojnar, Jerzy, additional, Kruzel, Tomasz, additional, Dziaczkowska, Joanna, additional, Markiewicz, Miroslaw, additional, Holowiecka-Goral, Aleksandra, additional, Karolczyk, Agnieszka, additional, Wylezol, Iwona, additional, Kusnierczyk, Piotr, additional, and Holowiecki, Jerzy, additional more...

Published
2006
Full Text
View/download PDF

14. Treosulfan + Fludarabine +/− Thymoglobulin - An Effective Low Toxicity Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia.

Author

Holowiecki, Jerzy, primary, Giebel, Sebastian, primary, Wojnar, Jerzy, primary, Krawczyk-Kulis, Malgorzata, primary, Wylezol, Iwona, primary, Markiewicz, Miroslaw, primary, Kruzel, Tomasz, primary, Holowiecka-Goral, Aleksandra, primary, and Kopera, Malgorzata, primary more...

Published
2005
Full Text
View/download PDF

15. Single Immunophenotypical Evaluation of Minimal Residual Disease before Autotransplantation of Non-Cryopreserved Bone Marrow Is Insufficient for Prediction of Outcome in High Risk Adult Acute Lymphoblastic Leukemia.

Author

Stella-Holowiecka, Beata M., primary, Jagoda, Krystyna, primary, Holowiecka-Goral, Aleksandra M., primary, Czerw, Tomasz, primary, Giebel, Sebastian, primary, Krawczyk-Kulis, Malgorzata, primary, and Holowiecki, Jerzy, primary more...

Published
2004
Full Text
View/download PDF

17. Treosulfan, cyclophosphamide and antithymocyte globulin for allogeneic hematopoietic cell transplantation in acquired severe aplastic anemia.

Author

Giebel S, Wojnar J, Krawczyk-Kulis M, Markiewicz M, Wylezoł I, Seweryn M, Holowiecka-Goral A, and Holowiecki J

Subjects
Adolescent, Adult, Busulfan therapeutic use, Disease-Free Survival, Follow-Up Studies, Graft vs Host Disease prevention & control, Histocompatibility Testing, Humans, Retrospective Studies, Severity of Illness Index, Time Factors, Transplantation, Homologous, Anemia, Aplastic drug therapy, Anemia, Aplastic therapy, Antilymphocyte Serum therapeutic use, Busulfan analogs & derivatives, Cyclophosphamide therapeutic use, Hematopoietic Stem Cell Transplantation
Abstract

To reduce the risk of graft rejection after allogeneic hematopoietic cell transplantation (alloHCT) for patients with acquired severe aplastic anemia (SAA), we introduced an intensified preparative regimen consisting of treosulfan 10 g/m2/d on days -7, -6, cyclophosphamide 40 mg/kg/d on days -5, -4, -3, -2 and anti-thymocyte globulin 2 mg/kg/d on days -3, -2, -1. Six patients with the history of multiple transfusions were treated with alloHCT from either HLA-identical sibling (n=3) or an unrelated volunteer (n=3). Each, bone marrow and peripheral blood was used as a source of stem cells in three cases. All patients engrafted and achieved complete donor chimerism. None of the patients experienced severe organ toxicity. No severe acute graft-versus-host-disease (GVHD) was observed; two patients experienced extensive chronic GVHD. At the median follow-up of 14.5 (13-27) months all patients remained alive and disease-free. Our observation indicates that treosulfan + cyclophosphamide + antithymocyte globulin conditioning is well-tolerated and allows stable engraftment in acquired SAA. more...

Published
2006

18. The incidence and risk factors for chronic graft-versus-host-disease.

Author

Wojnar J, Giebel S, Holowiecka-Goral A, Krawczyk-Kulis M, Markiewicz M, Wozniczka K, and Holowiecki J

Subjects
Adolescent, Adult, Child, Chronic Disease, Cohort Studies, Disease-Free Survival, Female, Follow-Up Studies, Graft vs Host Disease mortality, Hematopoietic Stem Cell Transplantation statistics & numerical data, Humans, Leukemia therapy, Living Donors, Lymphoma, Non-Hodgkin therapy, Male, Middle Aged, Multiple Myeloma therapy, Multivariate Analysis, Myelodysplastic Syndromes therapy, Retrospective Studies, Risk Factors, Transplantation, Homologous statistics & numerical data, Graft vs Host Disease epidemiology, Hematopoietic Stem Cell Transplantation adverse effects, Incidence
Abstract

Objectives: Chronic graft-versus-host-disease (cGVHD) deteriorates survival and quality of life after allogeneic hematopoietic cell transplantation (alloHCT). We evaluated the incidence and risk factors for this complication based on a single-center experience., Methods: 255 consecutive patients, aged 29 (10-56) years, who survived without disease progression after alloHCT performed between 1992-2003 were included in the analysis. The preparative regimen was myeloablative, donors were either related (n=177) or unrelated volunteers (URD-HCT) (n=78)., Results: Cumulative incidence of the overall and extensive cGVHD equaled 48% and 22%, respectively. In a multivariate analysis the following factors were associated with increased risk of cGVHD: preceding grade II-IV acute GVHD, recipient age > or =40 years, URD-HCT, the diagnosis of chronic myeloid leukemia (CML) or myelodysplastic syndrome, and CD3 cell dose 50 x 10(6)/kg. Similar factors, excluding recipient age contributed to increased risk of extensive cGVHD, however, the cut-point for CD3 cell dose was 100 x l0(6)/kg and the use of steroids for acute GVHD prophylaxis was found an additional risk factor. In a CML subgroup the risk of cGVHD was increased for patients previously treated with interferon., Conclusions: Various recipient-, donor-, and procedure-related factors are related to the risk of cGVHD. Individualized treatment and modification of risk factors may contribute to improved outcome. more...

Published
2006